These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 6506979

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
    Evtushenko SK.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Dec; 76(12):1797-1802. PubMed ID: 1015115
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation].
    Antonini F, Baroni A, Roveyaz L.
    Sist Nerv; 1970 Dec; 22(2):74-81. PubMed ID: 5504560
    [No Abstract] [Full Text] [Related]

  • 10. Amantadine hydrochloride in treatment of Parkinsonism.
    Nagaswami S, Nagaswami R.
    Dis Nerv Syst; 1973 Dec; 34(5):253-8. PubMed ID: 4782280
    [No Abstract] [Full Text] [Related]

  • 11. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T, Giovannini P, Girotti F, Parati E, Pederzoli M, Scigliano G.
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [Abstract] [Full Text] [Related]

  • 12. [Long-term levodopa syndrome. Report of a clinical case].
    Bossi L, Nobili M.
    Arch Sci Med (Torino); 1978 Dec; 135(4):637-9. PubMed ID: 756726
    [Abstract] [Full Text] [Related]

  • 13. [Certain features of the clinical picture and pathomorphology of Parkinson disease of different etiology].
    Martynov IuS, Zenkevich GS, Tochilovskiĭ AS.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980 Dec; 80(7):1033-9. PubMed ID: 7415721
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [Abstract] [Full Text] [Related]

  • 16. [Combined treatment of parkinsonism with L-dopa and Parkopan].
    Lukasiewicz K.
    Wiad Lek; 1977 May 15; 30(10):775-7. PubMed ID: 867994
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Our experience in the treatment of the parkinsonian syndrome with L-dopa. I. Evaluation of the clinical results].
    Bergamini L, Bonzanino O, Brignolio F, Fabiani A, Fariello R, Mombelli AM, Mutani R, Pisani W, Postir A, Riccio A, Sabbatini F, Sandigliano G, Schiffer D.
    Riv Patol Nerv Ment; 1969 Oct 15; 90(5):329-49. PubMed ID: 5406104
    [No Abstract] [Full Text] [Related]

  • 19. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T, Yahr MD.
    Ann Neurol; 1995 Jan 15; 37(1):95-8. PubMed ID: 7818264
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep 15; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.